For clinical translation, FGFR3 immunohistochemistry (IHC) has been established as a useful screening tool for detecting FGFR3 alterations and can be incorporated into the diagnostic workflow for IDH-wildtype gliomas (Lasorella et al., 2017; Schittenhelm et al., 2021). Here, FGFR3 is linked to glioma.